Budesonide and formoterol fumarate dihydrate
Pro Research Analysisby 
Searched over 200M research papers
Budesonide and Formoterol Fumarate Dihydrate: Pharmacokinetics, Efficacy, and Safety
Introduction to Budesonide and Formoterol Fumarate Dihydrate
Budesonide and formoterol fumarate dihydrate are commonly used in combination for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta-2 agonist that helps relax bronchial muscles, improving airflow and reducing symptoms.
Pharmacokinetics of Budesonide/Formoterol Combinations
Co-Suspension Delivery Technology
Recent studies have explored the pharmacokinetics of budesonide/formoterol combinations using innovative co-suspension delivery technology. This technology ensures consistent aerosol performance, which is crucial for effective drug delivery in respiratory conditions. A phase 1 study compared the pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) with a dry powder inhaler (DPI) formulation. The study found that systemic exposure to budesonide and formoterol was higher for BGF MDI and BFF MDI compared to BUD/FORM DPI, but all treatments were well tolerated.
Dose Proportionality and Ethnic Variability
Another study assessed the pharmacokinetics and safety of BGF MDI and glycopyrronium/formoterol fumarate dihydrate (GFF MDI) in healthy Chinese adults. The results indicated that budesonide exposure increased dose proportionally, and the pharmacokinetic parameters were comparable to those reported in Western and Japanese populations, suggesting that the doses are appropriate across different ethnic groups. Similarly, a study in Japanese adults confirmed that both doses of BGF MDI were well tolerated and showed dose-proportional systemic exposure to budesonide.
Efficacy in Asthma and COPD
Asthma Management
Budesonide/formoterol fumarate dihydrate is widely used in asthma management, particularly in adolescents and adults. The combination is effective in reducing exacerbations that require oral corticosteroids and may also reduce the total intake of inhaled corticosteroids over time. However, its efficacy in reducing hospital admissions and emergency room visits is less well documented, and further non-pharmaceutical company-sponsored research is needed.
COPD Treatment
In COPD, budesonide/formoterol combinations have shown significant benefits. The TELOS study demonstrated that BFF MDI improved lung function and reduced the rate of moderate/severe exacerbations compared to its monocomponents and a dry powder inhaler formulation. The ETHOS study further confirmed that BGF triple therapy reduced exacerbation rates and improved lung function, symptoms, and quality of life across different blood eosinophil ranges, supporting its use in patients with an exacerbation history and eosinophil counts ≥100 cells/mm³.
Safety Profile
Adverse Events and Tolerability
Across multiple studies, budesonide/formoterol combinations have been well tolerated. Common adverse events were mild to moderate in severity, and the incidence of pneumonia was low. The safety profiles were consistent across different formulations and ethnic groups, indicating a broad applicability of these treatments .
Conclusion
Budesonide and formoterol fumarate dihydrate combinations, particularly those using co-suspension delivery technology, offer effective and well-tolerated treatment options for asthma and COPD. These combinations improve lung function, reduce exacerbation rates, and enhance the quality of life for patients. The pharmacokinetic profiles are consistent across different populations, supporting their global use in respiratory disease management. Further research is needed to explore their impact on hospital admissions and emergency room visits in asthma patients.
Sources and full results
Most relevant research papers on this topic